Author

P. G. Schultz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Organism:human· 2 Organism:non-human primate· 1 Assay:proteomics· 1

Frequent Co-Authors

C. W. McNamara· 4 shared A. K. Chatterjee· 3 shared A. K. Gupta· 3 shared A. K. Woods· 3 shared M. A. Bakowski· 2 shared M. G. Kirkpatrick· 2 shared N. Beutler· 2 shared S. B. Joseph· 2 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

C. W. McNamara

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A Prodrug Strategy to Reposition Atovaquone as a Long-Acting Injectable for Malaria Chemoprotection

A. K. Gupta, A. M. Eliasen, W. Andahazy, F. Zhou, K. Henson, V. Chi, A. K. Woods, S. B. Joseph, K. L. Kuhen, J. Wisler, H. Ramachandruni, J. Duffy, J. N. Burrows, E. Vadas, A. Slade, , A. K. Chatterjee

This paper develops three prodrug formulations of atovaquone for long-acting injectable malaria chemoprotection, showing two maintain therapeutic plasma levels for over 70 and 30 days in monkeys.

bioRxiv · Feb 8, 2024 · PreprintPharmacology & Toxicology

Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Covalent Warhead

N. G. R. D. Elshan, K. C. Wolff, L. Riva, A. K. Woods, G. Grabovyi, K. Wilson, A. Rahimi, J. Pedroarena, S. Ghorai, A. K. Gupta, A. Nazarian, F. Weiss, Y. Liu, W. Mazumdar, L. Song, , A. K. Chatterjee

This paper introduces CMX990, a potent SARS-CoV-2 3CL protease inhibitor with improved potency and clearance compared to nirmatrelvir, advancing to Phase 1 clinical trials.

bioRxiv · Oct 24, 2023Microbiology

Pharmacological and genetic activation of cAMP synthesis disrupts cholesterol utilization in Mycobacterium tuberculosis

K. M. Wilburn, C. R. Montague, B. Qin, A. K. Woods, M. S. Love, C. W. McNamara, P. G. Schultz, T. L. Southard, L. Huang, H. M. Petrassi, B. C. VanderVen

This paper identifies a small molecule agonist of Mtb adenylyl cyclase Rv1625c that inhibits cholesterol utilization and disrupts Mtb pathogenesis in mice.

bioRxiv · Aug 3, 2021Microbiology

Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19

M. A. Bakowski, N. Beutler, E. Chen, T.-T. H. Nguyen, M. G. Kirkpatrick, M. Parren, L. Yang, J. Ricketts, A. K. Gupta, M. V. Hull, P. G. Schultz, D. R. Burton, A. K. Chatterjee, C. W. McNamara, T. F. Rogers

The paper identifies 66 compounds that inhibit SARS-CoV-2 replication and 24 that synergize with remdesivir, suggesting potential oral drug repositioning candidates for COVID-19.

Nature Communications · Jun 3, 2021Peer-reviewedMicrobiology